Oncology

Interim data from an ongoing study demonstrate continuing efficacy in B-NHL, CLL, and FL.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Oncternal will soon initiate a phase 1/2 dose-escalation study of ONCT-808.